Stanford V

Stanford V is a combination chemotherapy regimen developed as a first-line treatment for Hodgkin lymphoma. It was designed to maintain high remission rates while reducing acute and long-term toxicities such as pulmonary damage, infertility, and secondary malignancies compared to older regimens like ABVD. The regimen includes the following drugs: - A mustard derivative (commonly mechlorethamine/chlormethine) - Doxorubicin (an anthracycline anti-tumor antibiotic) - Vinblastine (a vinca alkaloid cell toxin) - Vincristine (another vinca alkaloid cell toxin) - Bleomycin (an anti-tumor antibiotic) - Etoposide (a DNA-damaging agent/topoisomerase II inhibitor) - Prednisone (a corticosteroid) Stanford V is typically administered over 8–12 weeks with accompanying radiation therapy tailored based on response and disease stage. The approach aims to reduce cumulative exposure to certain agents and limit radiation fields, thereby decreasing late toxicities while maintaining efficacy[1][2][3][4].

Other names

Stanford FiveStanford V regimen